Aimed Monthly
This issue of Aimed Monthly includes a U.S. Supreme Court decision on convicting prescribers under the Controlled Substances Act, two webinars for employers, a new biomarker fact sheet, and much more.
|
|
|
Chronic Disease Coalition and Aimed Alliance Inform Employees of Their Rights Under the ADA
In a webinar now available online, Aimed Alliance joined the Chronic Disease Coalition to inform employed health care consumers of their rights under the Americans with Disabilities Act (ADA). The three-person panel focused on how employees with disabilities and chronic conditions, can advocate for themselves in the workplace. View the one-hour webinar here.
|
|
|
|
Aimed Alliance Releases New Fact Sheet
on Biomarker Testing
|
|
|
|
PACH and Aimed Alliance
Host Webinars for Employers on HR.com
|
|
|
Supreme Court Rules In Favor of Patient Access to Medications in Ruan v. U.S.
On June 27, the U.S. Supreme Court held in Ruan v. United States that prescribers of opioids and other controlled medications may not be convicted under the Controlled Substances Act for prescribing-related behavior unless a jury finds evidence of criminal intent beyond a reasonable doubt. The decision addresses a substantial source of health care provider reluctance to prescribe controlled medications for conditions like pain, opioid use disorder, anxiety, ADHD, and insomnia. Read the full opinion here.
For more information on the case, review Aimed Alliance member the Center for U.S. Policy’s June 27 tweets here and its December 2021 Supreme Court amicus brief here.
|
|
|
Four More States Expand Medicaid Postpartum Coverage
Maine, Minnesota, New Mexico, and Washington, D.C. have expanded Medicaid and CHIP coverage to 12 months after pregnancy. These expansions will ensure an additional 15,000 people gain access to health care coverage. Read more here.
|
|
|
FTC Launches Investigation into Six PBMs
On June 7, the Federal Trade Commission (FTC) launched an inquiry into six of the largest pharmacy benefit managers (PBMs). The FTC requested these PBMs provide information on their business practices to the FTC including how PBMs: (1) charge fees and clawbacks to unaffiliated pharmacies; (2) steer patients towards PBM-owned pharmacies; (3) unfairly audit independent pharmacies; (4) complicate methods for pharmacy reimbursements; (5) employ prior authorization policies and other administrative restrictions; (6) use specialty drug lists and specialty drug policies; and (7) use rebates and fees from drug manufacturers in formulary designs, and how these practices impact the cost of prescription drugs. Read more about the FTC inquiry here.
|
|
|
Digital Therapeutic Alliance Releases Report on Differences Between Prescription Digital Therapies and Wellness Apps
|
|
|
Copay Accumulators
Delaware – Copay accumulator ban bill SB 267 has passed the House and Senate!
Prior Authorization
California – Prior Authorization Reform Gold Card bill SB 250 is currently in the Assembly Committee on Health.
Louisiana – Prior Authorization Reform Gold Card Law SB 112 has been signed by Governor!
.
|
|
|
Aimed Alliance Releases Biomarker Maps
Aimed Alliance has launched two new maps to track active and enacted biomarker legislation. Biomarker testing provides health care professionals with important information that can help them select and monitor treatments and develop more personalized treatment plans for patients. Yet, due to lack of coverage and burdensome prior authorization policies, these tests are not as widely available as they should be. Therefore, states have begun introducing legislation that would require health plans to cover biomarker testing and limit how health plans can impose prior authorization on biomarker testing. View our Active Legislation Map here and our Enacted Laws Map here.
|
|
Contact Us
Questions, comments, suggestions, or feedback? Send us an email.
|
|
|
|
|
